Psychiatric drug developer Alto Neuroscience files for $100M IPO

ismagilov Alto Neuroscience ( ANRO ) has filed to raise around $100M through an initial public offering. While the psychiatric drug developer didn’t specify terms in its SEC filing , it did indicate it was looking to raise approximately $100M, a number that is likely a placeholder and subject to change. Alto hopes to list its shares on NYSE under the symbol ANRO. Bookrunners include Jefferies, TD Cowen, Stifel, William Blair and Baird. Based in Los Altos, Calif., Alto’s two lead drug candidates, ALTO 100 and ALTO 300, are in Phase 2 testing for the treatment of major depressive disorder. More on Alto Neuroscience, Inc. Financial information for Alto Neuroscience, Inc.